# A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

> **NCT05028751** · PHASE1,PHASE2 · TERMINATED · sponsor: **Kronos Bio** · enrollment: 24 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Relapsed Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Lanraplenib
- **DRUG:** Gilteritinib

## Key facts

- **NCT ID:** NCT05028751
- **Lead sponsor:** Kronos Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-05
- **Primary completion:** 2024-04-09
- **Final completion:** 2024-04-09
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05028751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05028751, "A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT05028751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*